PFS
CODX

Prospera Financial Services’s Co-Diagnostics CODX Stock Holding History

Prospera Financial Services’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-85
Closed -$16K – 1788
2022
Q1 		$16K Buy
+85
New +$17.6K ﹤0.01% 1822
2020
Q4 		– Sell
-82
Closed -$33K – 836
2020
Q3 		$33K Buy
+82
New +$42.1K 0.01% 753

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prospera Financial Services's CODX Position: Q2 2022 in Review

Prospera Financial Services sold out of Co-Diagnostics (CODX) in Q2 2022, closing a stake of 85 shares — an estimated $16K sold.

Prospera Financial Services first reported a position in CODX in Q3 2020 and held it in 2 quarters. The position peaked at $33K in Q3 2020. 69 funds tracked by Wall St. Rank hold CODX as of Q2 2022.

  • Prospera Financial Services reported no remaining Co-Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 85 Co-Diagnostics shares in Q2 2022, an estimated $16K.
  • Prospera Financial Services first reported a position in Co-Diagnostics in Q3 2020 and held it in 2 quarters.
  • Prospera Financial Services's Co-Diagnostics position peaked at $33K in Q3 2020.
  • 69 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.